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ABSTRACT 
The purpose of the study was to determine the effect of vitamin D 
supplementation on bone turnover and bone loss in elderly women. 
Three hundred forty-eight women, ages 70 yr and older, were ran- 
domized to receive 400 IU vitamin D, ner dav (n = 177) or nlacebo 
(n = 1711, double-blind, for a period ofi yr. M& outcome measures 
were bone mineral density of both hips (femoral neck and trochanter) 
and the distal radius, as well as biochemical markers of bone turn- 
over. The effect of vitamin D supplementation was expressed as the 
difference in mean (percentage) change between the placebo group 
and the vitamin D group. 
The measurements were repeated in 283 women after 1 yr and in 
248 women after 2 yr. Vitamin D supplementation significantly in- 
creased serum 25hydroxyvitamin D (250HD) (+35 nmol/L) and 1,25- 
dehvdroxwitamin D 11.25-(OHLD1(+7.0 DmolL) levels and urinarv 
cal&n-&eatinine r&os (+0:5%) and significantly decreasei 
PTH(l-84) secretion (-0.74 pmol/L) after 1 yr. No effect was found 
for the parameters of bone turnover. The effect on the bone mineral 
density of the left femoral neck was + 1.8% in the first yr, +0.2% in 
the second yr, and + 1.9% during the whole period (95% confidence 
interval 0.4,3.4%). At the right femoral neck the effects were + 1.5%, 
+ l.l%, and +2.6% (confidence interval 1.1, 4.0%), respectively. No 
effect was found at the femoral trochanter and the distal radius. 
Supplementation with 400 IU vitamin D, daily in elderly women 
slightly decreases PTH secretion and increases bone mineral density 
at the femoral neck. (J Clin Endocrinol Metub 80: 1052-1058, 1995) 
V ITAMIN D deficiency is common in elderly people be- cause of lesser exposure to sunlight, decreased effi- 
ciency of the skin in producing vitamin D, and deficient 
nutrition (1, 2). It may be an important risk factor for hip 
fractures, which are a major cause of morbidity and mortality 
in the elderly. One yr after a fracture, mobility is restored in 
less than half of the patients, and about 20% of the patients 
will have died (3). Although true osteomalacia is rare, a 
suboptimal vitamin D status impairs the production of 1,25- 
dihydroxyvitamin D (1,25-(OH),D), which is essential for 
active intestinal calcium absorption. The ensuing secondary 
hyperparathyroidism will result in increased bone turnover 
and predominantly cortical bone loss, thus increasing the risk 
of fractures (4). Patients with a hip fracture often have lower 
vitamin D levels than do controls of similar age (5,6). More- 
over, positive correlations of vitamin D levels with bone 
mineral density (BMD) of the proximal femur and vertebrae 
have been found in elderly groups and among younger 
women with a poor vitamin D status (7, 8). 
Vitamin D supplementation of 400 IU daily in elderly 
people has little or no side effects and improves vitamin D 
status. In elderly people who are 25-hydroxyvitamin D 
(250HD)-deficient, supplementation increases serum 1,25- 
(OH),D levels and intestinal calcium absorption and de- 
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creases the secretion of PTH (9,101. This suggests that vita- 
min D supplementation may reduce bone turnover and bone 
loss and consequently may lower fracture incidence. How- 
ever, experimental data from randomized, double-blind tri- 
als are scarce. Dawson-Hughes et al. (11) observed that vi- 
tamin D supplementation reduced wintertime bone loss 
from the spine in a group of postmenopausal women, 
whereas in another study (12), no effect of a vitamin D sup- 
plement on appendicular bone loss was found in men. There 
is also some evidence that an annual injection of vitamin D 
protects against fractures (13). In a recent study (141, a daily 
supplement of 800 IU vitamin D, and 1200 mg calcium re- 
duced bone loss and the incidence of hip fractures in elderly 
women, but to what extent vitamin D caused this effect 
cannot be determined. 
Inasmuch as vitamin D supplementation may offer a safe 
and substantial contribution to the prevention of osteopo- 
rosis and hip fractures in the elderly, we studied the effect of 
a daily supplement of 400 IU vitamin D, during a 2-yr period 
on bone turnover and bone loss from the hip and distal 
radius, in a double-blind, placebo-controlled trial in women 
ages 70 yr and older. 
Materials and Methods 
Study population 
Elderly people ages 70 yr and older were asked to participate in a 
clinical trial on the effect of vitamin D supplementation on the incidence 
of hip fractures (15). Exclusion criteria were hip fracture in the past, total 
hip prosthesis, and recent history of urolithiasis, hypercalcemia, or sar- 
coidosis. Female residents of homes for the elderly and apartments for 
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the elderly were asked to participate in an additional study involving 
BMD and biochemical measurements. The women had to be reasonably 
mobile in order to be able to visit the hospital for BMD measurements, 
which were performed at baseline (to), after 1 yr (t,), and after 2 yr (t2). 
The protocol was approved by the hospital Ethical Committee, and all 
participants gave informed consent. 
Intervention, randomization, and compliance 
The subjects were randomized to receive either 400 IU vitamin D, or 
placebo, 1 tablet daily, during a 2-yr study. Randomization was per- 
formed by the hospital pharmacy, and double-blinding was assured. 
Compliance was established by questionnaire, by pill counting, and by 
measuring serum 250HD levels in blood at t, and t,. If participants were 
suspected of poor compliance resulting from memory problems, the 
nursing staff were asked to supervise the taking of the trial medication 
or to administer it. 
BMD measurements 
BMD was measured at t,,, t,, and t2 by single-photon absorptiometry 
(SPA, Norland OsteoAnalyzer, Norland Corp., Fort Atkinson, WI) at the 
distal radius of the dominant foreann. The long-term coefficient of variation 
(CV) in a group of 27 volunteers and osteoporotic patients was 3.1% (un- 
published local data). BMD of both hips was measured using dual-energy 
x-ray absorptiometry (DXA, Norland XR-26) at the femoral neck and tro- 
chanter. After collecting the data, all DXA scans were reanalyzed with the 
most recent Norland software version 2.3.0, optimizing the localization and 
angle of the regions of interest in subsequent scans of the subjects in order 
to enhance the intraindividual precision. The long-term CV in a group of 
50 volunteers and osteoporotic patients was 2.1% for the femoral neck and 
2.4% for the femoral trochanter (unpublished local data). During the study 
period, the drift did not exceed 0.5%, as measured daily using a spine 
phantom. 
Questionnaires 
Height and body weight were measured while the participants wore 
indoor clothes and no shoes. Height was measured using a stadiometer. 
Participants were asked to bring their current medication. They were 
also asked whether preparations containing vitamin D had been used at 
any time during the previous 12 months. Current calcium intake was 
estimated at to, t,, and t, using a questionnaire restricted to dairy prod- 
ucts, which underestimated calcium intake by 200-300 mg/day (16). 
Biochemical measurements 
Blood samples and 2-h fasting urine (17) were obtained from fasting 
subjects at t, and t,. Osteocalcin was measured using an RIA kit from 
the Incstar Corporation (Stillwater, MN). Serum intact PTH [PTH(l-84)J 
was measured in plasma using a two-step immunochemical method 
involving amino-terminal immuno-extraction followed by a midregion 
immunoassay. The interassay CV of this method is 10.2% (18). Serum 
calcitonin was measured in 200 women at to and t2 using an RlA kit from 
the Nichols Institute (San Juan Capistrano, CA) to measure native cal- 
citonin (l-32). The serum 250HD and 1,25-(OH),D measurements at t, 
and t, were performed in the same run after storage at -20 C using a 
competitive protein-binding assay after purification by acid phase ex- 
traction and gradient high performance liquid chromatography. The 
intraassay and interassay CVs are 5% and 6% for 250HD and 6% and 
15% for 1,25-(OH),D, respectively (19). Serum bone-specific alkaline 
phosphatase was determined using a wheat germ lectin-precipitation 
method, with an interassay CV of 6.8% (20). Measurement of serum 
sex-hormone binding globulin (SHBG) at to was performed using an 
immunoradiometric assay kit fromFarmos Diagnostica (Oulunsalo, Fin- 
land) with an interassay CV of 5.3%. Urinary hydroxyproline was mea- 
sured by high performance liquid chromatography with an interassay 
CV below 3.2% (21) and expressed as hydroxyproline/creatinine ratio. 
Serum alkaline phosphatase, calcium, phosphate, albumin, and creati- 
nine were measured using standard laboratory methods. Serum calcium 
was corrected for serum albumin using the following equation: corrected 
calcium = calcium + [40 - albumin (g/L)] X 0.02 mmol/L. 
Statistical analysis 
Statistical analysis was performed using SPSS-PC. The data on the 
treatment assignment were joined to the other data immediately before 
the statistical analyses and were made anonymous in order to maintain 
blinding. Differences in drop-out rates were analyzed with ,$ tests with 
Yates correction or Fisher’s Exact Tests when appropriate. The effect of 
vitamin D supplementation on the biochemical variables was defined as 
the difference in mean change of biochemical measurements between 
the vitamin D group and the placebo group and was analyzed with 
analysis of variance. The change in BMD during the whole period was 
analyzed with analysis of variance for repeated measurements. For each 
participant, bone loss was calculated as percentage change. The effect of 
vitamin D supplementation was defined as the difference in mean 
change of BMD (%) between the vitamin D group and the placebo group 
during the period at issue; a positive effect indicated a relative gain in 
the vitamin D group. The effect of vitamin D supplementation at t, and 
t,, and modification of this effect, was analyzed with linear multiple 
regression analysis, checking for linearity of the relation, normal dis- 
tributions, and constancy of variance of the residuals. The calcium intake 
was averaged for the study periods at issue. Other significant determi- 
nants of bone loss were added to the model to enhance precision and to 
correct for potential confounding variables. When necessary, logarith- 
mic transformations were performed to normalize variance for para- 
metric tests. Serum 250HD values were corrected for season according 
to a multivariate model (22). All reported P values are two-sided. 
Results 
A total of 348 women were randomized to vitamin D (n = 
177) or placebo treatment (n = 171). The baseline characteristics 
are presented in Table 1. There were no substantial differences 
in these characteristics between the groups. One woman who 
appeared to have hypercalcemia at baseline was excluded from 
further participation. One participant in the vitamin D group 
reported a rash that disappeared after discontinuing the trial 
medication. At the second and third visit, 6 and 5 women in the 
placebo group and 7 and 2 women in the vitamin D group, 
respectively, seemed to be taking a supplement containing vi- 
tamin D, and these were excluded from the analysis. In 283 and 
248 women, respectively, the measurements were repeated at 
t, and t2. The reasons for not having a follow-up measurement 
are presented in Table 2. The drop-out rate was 19% in the first 
yr, 11% in the second yr, and 29% for the whole study period. 
The drop-out rate was somewhat greater in the placebo group, 
mainly because of a higher death rate (P = 0.12 in the first yr, 
P = 0.08 for the total period), although none of the differences 
were significant. 
Compliance 
The compliance in the women who had repeated measure- 
ments was good. According to the yearly questionnaire, 85% 
used one tablet daily, and 14% used between three and six 
tablets weekly at t, as well as at t2. The analysis of the remaining 
tablets showed a slightly better compliance in the second study 
yr. In the first yr, 63% had used between six and seven tablets 
weekly, and 4% had used less than three weekly; in the second 
yr, these compliance rates were 78% and l%, respectively. Of 
the women receiving the vitamin D supplement, only 5 par- 
ticipants (3%) did not achieve a serum 250HD level higher than 
30 nmol/L at t,, whereas 68.4% of the participants in the placebo 
group had serum levels below 30 nmol/L. 
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TABLE 1. Characteristics of 348 participants at baseline by intervention group 
Vitamin D (n = 177) Placebo (n = 171) 
Mean SD Mean SD 
Variable 
Age (yr) 80.1 5.6 80.6 5.5 
Years since menopause 32.6 7.5 32.3 6.5 
Body weight (kg) 70.6 10.9 71.5 11.7 
BMI (kg/cm’) 28.1 4.1 28.6 4.0 
BMD, left femoral neck (g/cm2) 0.697 0.111 0.707 0.106 
BMD, right femoral neck (g/cm”) 0.700 0.124 0.698 0.105 
BMD, left femoral trochanter (g/cm2) 0.614 0.113 0.630 0.111 
BMD, right femoral trochanter (g/cm”) 0.608 0.109 0.617 0.107 
BMD, distal radius (g/cm2) 0.316 0.078 0.318 0.083 
Skewed variable” median percentiles median percentiles 
250HD (nmol/L) 27.0 19-36 25.0 19-37 
1,25-(OHlaD (pmol/L) 110 89-138 111 go-131 
Calcium intake (mg/day)b 876 638-1101 859 644-1099 
SHBG (pmol/L) 59 41-79 55 39-72 
BMI, body mass index; BMD, bone mineral density; SHBG, serum sex-hormone binding globulin. 
a For skewed variables, median values and the 25th and 75th percentiles are given. 
b From dairy products. 
TABLE 2. Number of drop-outs by treatment category and follow- 
up year (Pl = placebo, Da = vitamin D) and significance of the 
difference during the whole period 
Reason for drop-out 
kr+h 
Pl D3 
t,+tt, 
Pl D3 
kr% 
P value 
Deceased 12 5 9 6 0.08 
Reported side effect 0 1 0 0 1.00 
Unable to visit hospi- 5” 1 3 1 0.17 
tal 
Other health problems 5 9” 3 8 0.23 
Not motivated 12 12 2 6 0.65 
PHP 0 0 0 1 1.00 
Hypercalcemia 0 1 0 0 1.00 
Use of bisphosphonate 2 0 0 0 0.29 
Total 36 29 17 22 0.75 
Remaining in study 283 248 
PHP, primary hyperparathyroidism. 
a Of whom 2 agreed to BMD measurements at t,, which are in- 
cluded in the results (total of 4). 
Biochemical results 
The biochemical measurements at t, and t, are presented 
in Table 3. Vitamin D supplementation significantly in- 
creased serum 250HD ( +35 nmol/L) and 1,25-(OH),D ( + 7.0 
pmol/L) levels at t,. The median serum PTH(l-84) value 
decreased in the vitamin D group, whereas there was a slight 
increase in the placebo group, the effect at t, (-0.74 pmol/L)) 
being statistically significant. Serum calcitonin increased in 
the group treated with vitamin D, but there was a similar 
increase in the placebo group. Although serum osteocalcin, 
alkaline phosphatase, bone alkaline phosphatase, and uri- 
nary hydroxyproline/creatinine demonstrated a slight rela- 
tive decrease at t,, this effect of vitamin D supplementation 
was not significant. A significant relative increase was ob- 
served for the urinary calcium/creatinine ratio (+0.5%). 
Bone mineral measurements 
Bone loss at t, and t, was expressed as the difference in 
mean change in BMD (%), as presented in Table 4 and Fig. 
1. To enhance precision, weight loss was used as a covariate 
for all measurement sites, and serum SHBG at baseline was 
used for the trochanter and distal radius, as these were sig- 
nificantly related to bone loss at these measurement sites. 
Adding the covariates to the model did not markedly alter 
the results. The effect of vitamin D supplementation at t, was 
an increase in BMD of 1.9% for the left and 2.6% for the right 
femoral neck. During the whole period (ti and t2), a statis- 
tically significant gain was observed at the left and right 
femoral neck (P = 0.01 and P = 0.002, respectively, analysis 
of variance for repeated measurements), and no significant 
effects were observed for the other measurement sites. In 
multiple regression analysis, the effects seemed to be most 
prominent in the first study yr (to to tl), in which the differ- 
ences in change between the groups were 1.5% and 1.8% for 
the left and right femoral neck, respectively. In the second 
study yr (ti to t2), minor positive effects were observed as 
well, but these were not significant. No significant effects 
were found at the left and right trochanter and the distal 
radius. 
Modification 
Baseline serum 250HD, serum SHBG, and calcium intake 
were tested as potential modifiers of the effect of vitamin D 
on bone loss during the first yr. The effect of vitamin D 
supplementation seemed to be independent of baseline se- 
rum 250HD as well as of serum 250HD corrected for season 
(all P > 0.20). A greater effect in favor of the vitamin D group 
was found at higher serum SHBG levels at all measurement 
sites. This modification was significant at the left femoral 
neck (P = 0.01) and right femoral neck (P = 0.05), and of 
borderline significance at the left trochanter (P = O.OB), but 
not at the other measurement sites. At the left trochanter, a 
greater effect of vitamin D supplementation was found at 
lower calcium intakes (P = 0.004). In contrast, the effect of 
vitamin D supplementation was greater at higher calcium 
intakes at the right femoral neck (P = 0.03). 
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TABLE 3. Mean and standard deviation (SD) or median and 25th and 75th percentiles for biochemical measurements at baseline (to) and 
after 1 yr intervention (t,) with placebo (Pl) or vitamin D (D,) in 270 participantsa 
Mesn 
to 
SD Mean 
t1 
b/D3 
SD 
Serum concentration 
Calcium (corrected) (mmol/L) 
Phosphate (mmol/L) 
Serum concentration (skewed) 
250HD (nmol/L) 
1,25-(OH),D (pmol/L) 
PTH(l-84) (pmol/L) 
Calcitonin (pg/mLY 
Osteocalcin (kg/L) 
Alkaline phosphatase (U/L) 
Bone alkaline phosphatase 
cum 
Creatinine (PmoLL) 
Hydroxyproline/creatinine 
(~mol/mmol)d 
Calciumcreatinine (mmoll 
mmol)” 
Pl 
DS 
Pl 
D3 
Pl 
D3 
Pl 
Da 
Pl 
DS 
Pl 
% 
Pl 
D3 
Pl 
D3 
Pl 
D3 
Pl 
Da 
Pl 
D3 
Pl 
D, 
2.4 0.1 
2.4 0.1 
1.0 0.1 
1.1 0.1 
median percentiles 
26.0 19-37 
27.0 19-36 
114 go-135 
111 93-138 
3.5 2.7-5.0 
3.3 2.4-4.6 
5.2 2.8-9.5 
4.0 1.5-7.9 
3.4 2.7-4.5 
3.7 2.7-4.9 
66 55-78 
63 53-78 
28 22-34 
27 22-32 
83 76-94 
82 74-94 
20 17-26 
21 16-26 
0.31 0.17-0.47 
0.27 0.16-0.41 
2.4 
2.4 
1.1 
1.1 
median 
23.0 
62.0 
110 
115 
3.7 
3.1 
6.0 
5.6 
3.2 
3.3 
66 
62 
33 
28 
82 
83 
19 
19 
0.29 
0.27 
0.1 
0.1 
0.2 
0.1 
percentiles 
17-31 
52-70 
84-130 
94-133 
2.5-5.8 
2.3-4.1 
2.8-11.5 
3.2-8.0 
2.4-4.2 
2.4-4.4 
54-76 
53-74 
24-35 
22-34 
74-93 
75-96 
16-24 
16-24 
0.16-0.42 
0.18-0.46 
0.90 
0.83 
0.001 
0.03 
0.005 
0.38 
0.35 
0.41 
0.50 
0.83 
0.68 
0.03 
The P value (P,,, ) refers to the statistical significance of the difference in mean change between the groups. 
a Participants using vitamin D supplements at t, are excluded (n = 13). 
’ Measured in 192 women at t, and t,. 
’ Measured in 158 patients. 
d Hydroxyproline/creatinine ratio in fasting urine. 
e Calciumcreatinine ratio in fasting urine. 
TABLE 4. Mean change (%) in the first yr (n = 270), second yr (n = 241), and total period in the placebo (Pl) and vitamin D (Da) group, 
the difference in mean change between the groups and 95% confidence interval, and statistical significance over the whole period 
Left femoral neck 
Right femoral neck 
Left femoral trochanter 
Right femoral trochanter 
Distal radius 
diff 
diff 
diff 
diff 
diff 
-1.5 0.3 1.2 1.3 -0.3 1.6 
1.8 (0.6, 3.0) 0.2 (-1.4, 1.7) 1.9 (0.4,3.4) 0.01 
-0.9 0.5 -0.34 0.7 -1.4 1.2 
1.5 (0.4,2.6) 1.1 c-0.2,2.3) 2.6 (1.1, 4.0) 0.001 
-1.7 -1.0 0.9 0.4 -0.9 -1.1 
0.7 (-0.6, 1.9) -0.5 (-2.2, 1.3) -0.2 (-1.9, 1.5) 0.90 
-1.1 -1.5 0.3 0.8 -0.9 -0.9 
-0.4 (--1.7,0.9) 0.5 c-1.2,2.3) -0.0 (-1.7, 1.7) 0.52 
-1.5 -3.8 1.5 3.1 -2.4 -2.7 
-2.4 c-5.5,0.8) 1.6 (-3.3, 6.4) -0.3 (-4.9,4.3) 0.25 
a Analysis of variance for repeated measurements. 
Discussion 
We found that supplementation with 400 IU vitamin Ds daily 
in elderly women improved the vitamin D status to that of the 
young adult range (23), slightly increased serum 1,25-(OH),D lev- 
els, slightly decreased PTH secretion, and increased BMD at the 
femoral neck. No effect on the parameters of bone turnover was 
observed, except for a small increase in the urinary calcium/cre- 
atinine ratio. Higher serum levels of 1,25-(OH&D may increase 
calcitonin secretion in elderly women (241, but this was not con- 
firmed by our results. 
The increase in BMD at the femoral neck was most ap- 
parent in the first yr (between 1.5 and 1.8%), whereas during 
the second yr there was still some additional gain (0.2 and 
l.l%), although it was not statistically significant. Indeed, 
some of the effects of vitamin D supplementation can be 
expected to be confined to the first yr (4, 25). Vitamin D 
supplementation may increase calcium availability, which 
may promote the mineralization of previously underminer- 
alized bone and the rate at which new bone is mineralized 
(26). The lower serum PTH levels will reduce bone turnover, 
thus decreasing the remodeling space and the quantity of 
new bone with lower mineral content (25). However, this 
could not be confirmed by a decrease in the markers of bone 
turnover. Although all were lower in the vitamin D group, 
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effect on BMD (%) 
2 
1 
0 
I 
-3 : 
-4 F 
1”’ year 2nd year total period 
n left femoral neck Izd right femoral neck 0 left femoral troth. q right femoral troth. 
FIG. 1. Effect of vitamin D supplementation on bone loss by study yr. 
The standard error is indicated by error bars. * P < 0.05, ** P < 0.01. 
none of the observed effects were statistically significant. 
1,25-(OH),D is known to stimulate osteocalcin and alkaline 
phosphatase production in the osteoblasts, which may coun- 
teract the effect of lowering turnover (26). When the balance 
between bone resorption and formation is negative, a de- 
crease in bone turnover will lower the rate of age-related 
bone loss (27). This effect will persist for as long as vitamin 
D supplementation is continued. The small, nonsignificant 
benefit during the second yr suggests a decrease of the age- 
related bone loss, but a longer follow-up period would have 
been necessary to confirm this more subtle effect. 
Dawson-Hughes et al. (11) observed a reduction of win- 
tertime bone loss from the lumbar spine as a result of 
vitamin D supplementation in younger women, and no 
effect on whole-body BMD. Eighty percent of the skeleton 
is cortical bone. Therefore, they suggested that trabecular 
bone is more sensitive to vitamin D deficiency than cortical 
bone is. Heikinheimo et al. (13) found that vitamin D 
supplementation greatly reduced the incidence of upper 
limb fractures, whereas a much smaller and nonsignificant 
reduction in the incidence of lower limb fractures was 
observed. This suggests that the effect of vitamin D sup- 
plementation depends on the skeletal region rather than 
on the ratio of cortical to trabecular bone. In our study, the 
increase in BMD was confined to the femoral neck, an area 
with a relatively high content of cortical bone, and no effect 
of vitamin D supplementation was found at the femoral 
trochanter and distal radius, which are predominantly 
trabecular areas. We did not measure BMD at the lumbar 
spine, as this measurement has been found to be inaccurate 
because of the high prevalence of spinal osteoarthritis in 
elderly people (27). In a population of elderly women, 
Chapuy et al. (14) observed a greater effect of a combina- 
tion of 800 IU vitamin D and 1200 mg calcium daily on 
BMD of the proximal femur and serum PTH than was 
found in our study. It is unlikely that the higher dose of 
vitamin D is responsible for the difference in the results. 
The additional increase in serum 250HD when using a 
800-IU dose is negligible (9), which is confirmed by the 
similar increase of serum 250HD in both studies. Al- 
though mean baseline serum 250HD and age were similar, 
the dietary calcium intake was much lower in the Chapuy 
study, which may account for the higher baseline serum 
PTH levels and the subsequently greater reduction after 
supplementation. This suggests that the calcium supple- 
ment contributed substantially to the observed effects in 
this study. 
We expected participants with serum 250HD concen- 
trations below 30 nmol/L to benefit more from vitamin D 
supplementation than participants with higher levels. In a 
cross-sectional analysis of the baseline data in this group 
(22), we found a clear distinction between vitamin D- 
deficient and vitamin D-replete participants at a serum 
250HD of approximately 30 nmol/L. Higher serum PTH 
and osteocalcin and lower BMD values were observed 
only in participants with values below this threshold. Sur- 
prisingly, the effect of vitamin D supplementation was not 
significantly greater in participants with low baseline se- 
rum 250HD levels than in those with higher levels. When 
the serum 250HD levels were corrected for the season of 
measurement, the results were similar. Only about 30% of 
the participants had baseline serum 250HD levels higher 
than 30 nmol/L, and this group may be too small to detect 
modification of the effect of vitamin D supplementation. 
At the left and right femoral neck and left trochanter, the 
effect of vitamin D supplementation was greater in par- 
ticipants with high serum SHBG than in those with lower 
serum levels. Inasmuch as serum SHBG has been found to 
be the main determinant of the levels of free estrogen in 
elderly women, it can be used as an inverse marker of 
remaining estrogen activity (28-30). High serum SHBG, 
i.e. low estrogen activity, may be associated with lower 
calcium absorption because of decreased sensitivity of the 
gut to 1,25-(OH),D or to a direct effect of estrogen on the 
gut (31, 32). Indeed, higher serum PTH levels were ob- 
served at baseline among participants in whom low serum 
250HD was combined with high serum SHBG (22). In this 
group, higher serum 1,25-(OH),D levels will be required 
to maintain adequate absorption, which will be possible 
only when the serum 250HD levels are sufficient. The 
active metabolite 1,25-(OH),D is essential for active intes- 
tinal calcium absorption. When calcium intake is high, the 
contribution of passive calcium diffusion to intestinal cal- 
cium absorption may be higher. The effect of vitamin D 
supplementation may be less in these subjects. This could 
only be confirmed at the left trochanter with high statis- 
tical significance, whereas (surprisingly) the opposite was 
found at the right femoral neck. 
It may be expected that an increase in BMD at the femoral 
neck will reduce the risk of hip fracture. However, quanti- 
fication of this reduction is difficult and may be different for 
femoral neck and trochanteric fractures. Using data from 
Cummings et al. (33) on the relation between BMD and frac- 
ture risk, the effect of vitamin D supplementation on BMD 
in this study would correspond with a reduction in the in- 
cidence of femoral neck fractures by 12-17%. The risk of 
trochanteric fractures may be unchanged or even decreased 
inasmuch as BMD of the femoral neck is a predictor of tro- 
chanteric fractures as well. 
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As could be expected in an elderly population, the drop- 
out rate was substantial. The total number of deaths was 
almost twice as high in the placebo group, which may bias 
the results. However, a higher number of frail elderly, who 
are more prone to bone loss, may have remained in the 
vitamin D supplemented group, so the true effect of vitamin 
D supplementation may be even greater rather than smaller. 
We conclude that vitamin D supplementation with 400 IU 
daily slightly increases serum 1,25-(OH),D and lowers PTH 
secretion without side effects. Bone loss is prevented at the 
femoral neck but not at the femoral trochanter and distal 
radius. The effect is independent of the baseline vitamin D 
status, but our data suggest that elderly women with little 
remaining estrogen activity benefit more than women with 
greater remaining estrogen activity. Therefore vitamin D 
supplementation may be a safe method for the prevention of 
hip fractures in the elderly. 
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